<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SULFAMETHOXAZOLE AND TRIMETHOPRIM- sulfamethoxazole and trimethoprimÂ injection, solutionÂ </strong><br>Teva Parenteral Medicines, Inc.<br></p></div>
<h1>Sulfamethoxazole and <br>Trimethoprim Injection USP </h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9b374c47-aa16-44b5-8eb3-9068c2ab7440"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
<p>9503</p>
<p>9514</p>
<p>9526</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim injection and other antibacterial drugs, sulfamethoxazole and trimethoprim injection should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_4b522ff7-4ee7-4055-83e8-140cc3b25110"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Sulfamethoxazole and Trimethoprim Injection USP, a sterile solution for intravenous infusion only, is a synthetic antibacterial combination product. Each mL contains: sulfamethoxazole, USP 80 mg; trimethoprim, USP 16 mg; benzyl alcohol 10 mg (1.0% v/v and 1.0% w/v) as a preservative; diethanolamine 3 mg (0.3% v/v and 0.3% w/v); ethyl alcohol 100 mg (12.3% v/v and 10.0% w/v); propylene glycol 400 mg (38.6% v/v and 40.0% w/v); sodium metabisulfite 1 mg as an antioxidant; water for injection q.s.; air replaced with nitrogen; pH adjusted with sodium hydroxide and/or hydrochloric acid if necessary. pH: 9.5 to 10.5. </p>
<p>Sulfamethoxazole, USP is <span class="Italics">NÂ <span class="Sup">1</span></span>-(5-methyl-3-isoxazolyl)sulfanilamide. It is an almost white, odorless, tasteless compound with the following structural formula:</p>
<div class="Figure">
<img alt="Sulfamethoxazole Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b89b5502-ce87-45a6-a43c-9891da3cfca4&amp;name=d39fe231-d9a6-4396-86ff-5ff23ee40e81-01.jpg"><p class="MultiMediaCaption">C<span class="Sub">10</span>H<span class="Sub">11</span>N<span class="Sub">3</span>O<span class="Sub">3</span>S       M.W. 253.28</p>
</div>
<p>Trimethoprim, USP is 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine. It is a white to light yellow, odorless, bitter compound with the following structural formula:</p>
<div class="Figure">
<img alt="Trimethoprim Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b89b5502-ce87-45a6-a43c-9891da3cfca4&amp;name=d39fe231-d9a6-4396-86ff-5ff23ee40e81-02.jpg"><p class="MultiMediaCaption">C<span class="Sub">14</span>H<span class="Sub">18</span>N<span class="Sub">4</span>O<span class="Sub">3 </span>      M.W. 290.3</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_454f69d7-ec87-4198-9e11-2fdb093377f9"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Following a 1 hour intravenous infusion of a single dose of 800 mg sulfamethoxazole and 160 mg trimethoprim to 11 patients whose weight ranged from 105 lbs to 165 lbs (mean, 143 lbs) the peak plasma concentrations of sulfamethoxazole and trimethoprim were 46.3 Â± 2.7 mcg/mL and 3.4 Â± 0.3 mcg/mL, respectively. Following repeated intravenous administration of the same dose at 8 hour intervals, the mean plasma concentrations just prior to and immediately after each infusion at steady state were 70.6 Â± 7.3 mcg/mL and 105.6 Â± 10.9 mcg/mL for sulfamethoxazole and 5.6 Â± 0.6 mcg/mL and 8.8 Â± 0.9 mcg/mL for trimethoprim. The mean plasma half-life was 12.8 Â± 1.8 hours for sulfamethoxazole and 11.3 Â± 0.7 hours for trimethoprim. All of these 11 patients had normal renal function, and their ages ranged from 17 to 78 years (median, 60 years).<span class="Sup">1</span></p>
<p>Pharmacokinetic studies in children and adults suggest an age-dependent half-life of trimethoprim, as indicated in the following table.<span class="Sup">2</span></p>
<a name="id_e36a7f9a-b7f0-4d48-8c0a-4c9e0711582d"></a><table border="single" width="371">
<col width="33.3%">
<col width="33.4%">
<col width="33.3%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Age</span></p>
<span class="Bold">(years)</span>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First"><span class="Bold">No. of</span></p>
<span class="Bold">Patients</span>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First"><span class="Bold">Mean TMP</span></p>
<span class="Bold">Half-life (hours)</span>
</td>
</tr>
<tr>
<td align="center" valign="top">&lt; 1</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">7.67</td>
</tr>
<tr>
<td align="center" valign="top">1 to 10</td>
<td align="center" valign="top">9</td>
<td align="center" valign="top">5.49</td>
</tr>
<tr>
<td align="center" valign="top">10 to 20</td>
<td align="center" valign="top">5</td>
<td align="center" valign="top">8.19</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="top">20 to 63</td>
<td class="Botrule" align="center" valign="top">6</td>
<td class="Botrule" align="center" valign="top">12.82</td>
</tr>
</tbody>
</table>
<p>Patients with severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> exhibit an increase in the half-lives of both components, requiring dosage regimen adjustment (see <span class="Bold"><a href="#i4i_dosage_admin_id_f8e9e6f6-444e-4d17-b9e3-824ae240f57d">DOSAGE AND ADMINISTRATION</a></span> section).</p>
<p>Both sulfamethoxazole and trimethoprim exist in the blood as unbound, protein-bound and metabolized forms; sulfamethoxazole also exists as the conjugated form. The metabolism of sulfamethoxazole occurs predominately by N<span class="Sub">4</span>-acetylation, although the glucuronide conjugate has been identified. The principal metabolites of trimethoprim are the 1- and 3-oxides and the 3â€™- and 4â€™-hydroxy derivatives. The free forms of sulfamethoxazole and trimethoprim are considered to be the therapeutically active forms. Approximately 70% of sulfamethoxazole and 44% of trimethoprim are bound to plasma proteins. The presence of 10 mg percent sulfamethoxazole in plasma decreases the protein binding of trimethoprim by an insignificant degree; trimethoprim does not influence the protein binding of sulfamethoxazole.</p>
<p>Excretion of sulfamethoxazole and trimethoprim is primarily by the kidneys through both glomerular filtration and tubular secretion. Urine concentrations of both sulfamethoxazole and trimethoprim are considerably higher than are the concentrations in the blood. The percent of dose excreted in urine over a 12 hour period following the intravenous administration of the first dose of 1200 mg of sulfamethoxazole and 240 mg of trimethoprim on day 1 ranged from 7% to 12.7% as free sulfamethoxazole and 17% to 42.4% as free trimethoprim; and 36.7% to 56% as total (free plus the N<span class="Sub">4</span>-acetylated metabolite) sulfamethoxazole. When administered together, neither sulfamethoxazole nor trimethoprim affects the urinary excretion pattern of the other. Both sulfamethoxazole and trimethoprim distribute to <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> and vaginal fluid; trimethoprim also distributes to bronchial secretions, and both pass the placental barrier and are excreted in breast milk.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dae14738-d900-4a43-a11e-286b1e46ecef"></a><a name="section-3.1"></a><p></p>
<h2>Microbiology</h2>
<p class="First">Sulfamethoxazole inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA). Trimethoprim blocks the production of tetrahydrofolic acid from dihydrofolic acid by binding to and reversibly inhibiting the required enzyme, dihydrofolate reductase. Thus, sulfamethoxazole and trimethoprim blocks two consecutive steps in the biosynthesis of nucleic acids and proteins essential to many bacteria.</p>
<p><span class="Italics">In vitro</span> studies have shown that <span class="product-label-link" type="condition" conceptid="4207042" conceptname="Viral resistance">bacterial resistance</span> develops more slowly with both sulfamethoxazole and trimethoprim in combination than with either sulfamethoxazole or trimethoprim alone. </p>
<p>Sulfamethoxazole and trimethoprim have been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Bold"><a href="#i4i_indications_id_02fc789f-25c2-4900-b8f4-9d51a68e571b">INDICATIONS AND USAGE</a></span>section.</p>
<p><span class="Bold">Aerobic gram-positive microorganisms</span></p>
<p><span class="Italics">Streptococcus pneumoniae</span></p>
<p><span class="Bold">Aerobic gram-negative microorganisms</span></p>
<p><span class="Italics">Escherichia coli</span> (including susceptible enterotoxigenic <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> implicated in travelerâ€™s <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>)<br><span class="Italics">Klebsiella</span> species<br><span class="Italics">Enterobacter</span> species<br><span class="Italics">Haemophilus influenzae</span><br><span class="Italics">Morganella morganii</span><br><span class="Italics">Proteus mirabilis</span><br><span class="Italics">Proteus vulgaris</span><br><span class="Italics">Shigella flexneri</span><br><span class="Italics">Shigella sonnei</span></p>
<p><span class="Bold">Other Organisms</span></p>
<p><span class="Italics">Pneumocystis jiroveci</span></p>
<p><span class="Bold">Susceptibility Testing Methods</span></p>
<p><span class="Italics">Dilution Techniques</span></p>
<p>Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method<span class="Sup">3</span> (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of sulfamethoxazole and trimethoprim powder. The MIC values should be interpreted according to the following criteria:</p>
<a name="id_30401dd8-21c2-4699-a0e3-e5663b870aae"></a><table border="none" width="432">
<col width="50.0%">
<col width="50.0%">
<tbody class="Headless">
<tr class="First Toprule"><td align="left" colspan="2" valign="top">For testing <span class="Italics">Enterobacteriaceae</span>
</td></tr>
<tr>
<td align="left" valign="top">MIC (mcg/mL)</td>
<td align="left" valign="top">Interpretation</td>
</tr>
<tr>
<td align="left" valign="top">â‰¤ 2/38</td>
<td align="left" valign="top">Susceptible (S)</td>
</tr>
<tr>
<td align="left" valign="top">â‰¥ 4/76</td>
<td align="left" valign="top">Resistant (R)</td>
</tr>
<tr><td align="left" colspan="2" valign="top">When testing either <span class="Italics">Haemophilus influenzae</span>Â <span class="Sup">a</span> or <span class="Italics">Streptococcus pneumoniae</span><span class="Sup">b</span>Â </td></tr>
<tr>
<td align="left" valign="top">MIC (mcg/mL)</td>
<td align="left" valign="top">Interpretation<span class="Sup">b</span>
</td>
</tr>
<tr>
<td align="left" valign="top">â‰¤ 0.5/9.5</td>
<td align="left" valign="top">Susceptible (S)</td>
</tr>
<tr>
<td align="left" valign="top">1/19 to 2/38</td>
<td align="left" valign="top">Intermediate (I)</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">â‰¥ 4/76</td>
<td align="left" valign="top">Resistant (R)</td>
</tr>
</tbody>
</table>
<p>Â  <span class="Sup">a</span> These interpretative standards are applicable only to broth microdilution susceptibility tests with <span class="Italics">Haemophilus influenzae</span> using <span class="Italics">Haemophilus</span> Test Medium (HTM).<span class="Sup">3</span></p>
<p><span class="Sup">b </span>These interpretative standards are applicable only to broth microdilution susceptibility tests using cation-adjusted Mueller-Hinton broth with 2% to 5% lysed horse blood.<span class="Sup">3</span></p>
<p>A report of â€œSusceptibleâ€? indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of â€œIntermediateâ€? indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of â€œResistantâ€? indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.</p>
<p><span class="Bold">Quality Control</span></p>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard sulfamethoxazole and trimethoprim powder should provide the following range of values:</p>
<a name="id_efb5f815-3078-47cd-9d88-d3f3604a26bf"></a><table border="none" width="439">
<col width="34.0%">
<col width="33.0%">
<col width="33.0%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top">Microorganism</td>
<td class="Toprule" align="left" valign="top"></td>
<td align="center" valign="middle">MIC (mcg/mL)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Escherichia coli</span></td>
<td align="left" valign="top">ATCC 25922</td>
<td align="center" valign="middle">â‰¤ 0.5/9.5</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Haemophilus influenzae</span><span class="Sup">c</span>
</td>
<td align="left" valign="top">ATCC 49247</td>
<td align="center" valign="middle">0.03/0.59 to 0.25/4.75</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">
<span class="Italics">Streptococcus pneumoniae</span><span class="Sup">d </span>
</td>
<td align="left" valign="top">ATCC 49619</td>
<td align="center" valign="middle">0.12/2.4 to 1/19</td>
</tr>
</tbody>
</table>
<p><span class="Sup">c </span>This quality control range is applicable only to <span class="Italics">Haemophilus influenzae</span> ATCC 49247 tested by broth microdilution procedure using <span class="Italics">Haemophilus</span> Test Medium (HTM).<span class="Sup">3</span></p>
<p><span class="Sup">d </span>This quality control range is applicable to tests performed by the broth microdilution method only using cation-adjusted Mueller-Hinton broth with 2% to 5% lysed horse blood.<span class="Sup">3</span></p>
<p><span class="Italics">Diffusion Techniques</span></p>
<p>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">4</span> requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 1.25/23.75 mcg of sulfamethoxazole and trimethoprim to test the susceptibility of microorganisms to sulfamethoxazole and trimethoprim.</p>
<p>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 1.25/23.75 mcg of sulfamethoxazole and trimethoprim disk should be interpreted according to the following criteria:</p>
<p>For testing either <span class="Italics">Enterobacteriaceae</span> or <span class="Italics">Haemophilus influenzae</span><span class="Sup">e</span></p>
<a name="id_40906728-9bcd-42b8-b5ba-597d7e7126b1"></a><table border="none" width="432">
<col width="28.6%">
<col width="71.4%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="center" valign="middle">Zone Diameter (mm)</td>
<td align="left" valign="top">Interpretation</td>
</tr>
<tr>
<td align="center" valign="top">â‰¥ 16</td>
<td align="left" valign="top">Susceptible (S)</td>
</tr>
<tr>
<td align="center" valign="top">11 to 15</td>
<td align="left" valign="top">Intermediate (I)</td>
</tr>
<tr class="Botrule Last">
<td align="center" valign="top">â‰¤ 10</td>
<td align="left" valign="top">Resistant (R)</td>
</tr>
</tbody>
</table>
<p><span class="Sup">e </span>These zone diameter standards are applicable only for disk diffusion testing with <span class="Italics">Haemophilus influenzae</span> and <span class="Italics">Haemophilus</span> Test Medium (HTM).<span class="Sup">4</span></p>
<p>When testing <span class="Italics">Streptococcus pneumoniae</span><span class="Sup">f</span></p>
<a name="id_8d53a4cc-9ed2-4ac4-9cf4-e3a3764c8648"></a><table border="none" width="432">
<col width="28.6%">
<col width="71.4%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="center" valign="top">Zone Diameter (mm)</td>
<td align="left" valign="top">Interpretation</td>
</tr>
<tr>
<td align="center" valign="top">â‰¥ 19</td>
<td align="left" valign="top">Susceptible (S)</td>
</tr>
<tr>
<td align="center" valign="top">16 to 18</td>
<td align="left" valign="top">Intermediate (I)</td>
</tr>
<tr class="Botrule Last">
<td align="center" valign="top">â‰¤ 15</td>
<td align="left" valign="top">Resistant (R)</td>
</tr>
</tbody>
</table>
<p><span class="Sup">f</span> These zone diameter interpretative standards are applicable only to tests performed using Mueller-Hinton agar supplemented with 5% defibrinated sheep blood when incubated in 5% <br>CO<span class="Sub">2.Â </span><span class="Sup">4</span></p>
<p>Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for sulfamethoxazole and trimethoprim.</p>
<p><span class="Bold">Quality Control</span></p>
<p>As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 1.25/23.75 mcg sulfamethoxazole and trimethoprim disk<span class="Sup">*</span> should provide the following zone diameters in these laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>:</p>
<a name="id_df986a5b-6c38-4477-ac09-ac51c78ec313"></a><table border="none" width="433">
<col width="36.1%">
<col width="28.3%">
<col width="35.5%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top">Microorganism</td>
<td class="Toprule" align="left" valign="top"></td>
<td align="left" valign="top">Zone Diameter Ranges (mm)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Escherichia coli</span></td>
<td align="left" valign="top">ATCC 25922</td>
<td align="center" valign="top">23 to 29</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Haemophilus influenzae</span><span class="Sup">g</span>
</td>
<td align="left" valign="top">ATCC 49247</td>
<td align="center" valign="top">24 to 32</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">
<span class="Italics">Streptococcus pneumoniae</span><span class="Sup">h</span>
</td>
<td align="left" valign="top">ATCC 49619</td>
<td align="center" valign="top">20 to 28</td>
</tr>
</tbody>
</table>
<p><span class="Sup">*</span>Mueller-Hinton agar should be checked for excessive levels of thymidine or thymine. To determine whether Mueller-Hinton medium has sufficiently low levels of thymidine and thymine, an <span class="Italics">Enterococcus faecalis </span>(ATCC 29212 or ATCC 33186) may be tested with sulfamethoxazole and trimethoprim disks. A zone of inhibition â‰¥ 20 mm that is essentially free of fine colonies indicates a sufficiently low level of thymidine and thymine.</p>
<p><span class="Sup">g </span>This quality control range is applicable only to <span class="Italics">Haemophilus influenzae</span> ATCC 49247 tested by a disk diffusion procedure using <span class="Italics">Haemophilus</span> Test Medium (HTM).<span class="Sup">4</span></p>
<p><span class="Sup">h </span>This quality control range is applicable only to tests performed by disk diffusion using Mueller-Hinton agar supplemented with 5% defibrinated sheep blood when incubated in 5% CO<span class="Sub">2</span>.<span class="Sup">4</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_02fc789f-25c2-4900-b8f4-9d51a68e571b"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of Sulfamethoxazole and Trimethoprim Injection USP and other antibacterial drugs, Sulfamethoxazole and Trimethoprim Injection USP should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_291effea-f6a5-44a4-83ec-9cf04572ec57"></a><a name="section-4.1"></a><p></p>
<h2>
<span class="Italics">Pneumocystis</span><span class="Italics">Jiroveci</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></h2>
<p class="First">Sulfamethoxazole and Trimethoprim Injection USP is indicated in the treatment of <span class="Italics">Pneumocystis <span class="Italics">jiroveci</span></span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> in children and adults.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_223f5468-099c-47a0-814f-65ce3e0f395d"></a><a name="section-4.2"></a><p></p>
<h2>Shigellosis</h2>
<p class="First">Sulfamethoxazole and Trimethoprim Injection USP is indicated in the treatment of <span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">enteritis</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Shigella flexneri </span>and <span class="Italics">Shigella sonnei</span> in children and adults.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b30f118c-9849-4b37-a38f-0fdceca1b8ea"></a><a name="section-4.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span></h2>
<p class="First">Sulfamethoxazole and Trimethoprim Injection USP is indicated in the treatment of severe or complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Escherichia coli</span>, <span class="Italics">Klebsiella</span> species, <span class="Italics">Enterobacter</span> species, <span class="Italics">Morganella morganii</span> and <span class="Italics">Proteus</span> species when oral administration of sulfamethoxazole and trimethoprim is not feasible and when the organism is not susceptible to single-agent antibacterials effective in the urinary tract.</p>
<p>Although appropriate culture and susceptibility studies should be performed, therapy may be started while awaiting the results of these studies.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_c4b1862b-37bf-46ac-872b-f06baa73f1c4"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Sulfamethoxazole and trimethoprim are contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to trimethoprim or sulfonamides, in patients with a history of drug-induced immune <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> with use of trimethoprim and/or sulfonamides, and in patients with documented <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span> due to <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span>. Sulfamethoxazole and trimethoprim are also contraindicated in pregnant patients and nursing mothers, because sulfonamides pass the placenta and are excreted in the milk and may cause <span class="product-label-link" type="condition" conceptid="4326231" conceptname="Kernicterus">kernicterus</span>. Sulfamethoxazole and trimethoprim are contraindicated in pediatric patients less than 2 months of age.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_9db29e7b-aa2a-4396-9537-a48184e3f49a"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d6ef8ae8-ba0f-40c6-8720-5de67afdc512"></a><a name="section-6.1"></a><p></p>
<h2>Â <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> and Other Fatal Reactions</h2>
<p class="First"><span class="Bold">FATALITIES ASSOCIATED WITH THE ADMINISTRATION OF SULFONAMIDES, ALTHOUGH RARE, HAVE OCCURRED DUE TO SEVERE REACTIONS, INCLUDING <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">STEVENS-JOHNSON SYNDROME</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">TOXIC EPIDERMAL NECROLYSIS</span>, FULMINANT <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">HEPATIC NECROSIS</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">AGRANULOCYTOSIS</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">APLASTIC ANEMIA</span>, AND OTHER <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">BLOOD DYSCRASIAS</span>.</span></p>
<p><span class="Bold">SULFONAMIDES, INCLUDING SULFONAMIDE-CONTAINING PRODUCTS SUCH AS SULFAMETHOXAZOLE AND TRIMETHOPRIM INJECTION, SHOULD BE DISCONTINUED AT THE FIRST APPEARANCE OF <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">SKIN RASH</span> OR ANY SIGN OF ADVERSE REACTION.</span> In rare instances, a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> may be followed by a more severe reaction, such as <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, and serious <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood disorders</span> (see <span class="Bold"><a href="#i4i_precautions_id_ef3d732a-29fb-4d89-aa3b-d8cdbe2e461c">PRECAUTIONS</a></span>). Clinical signs, such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> may be early indications of serious reactions.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, and pulmonary infiltrates are <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> of the respiratory tract that have been reported in association with sulfonamide treatment.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ca11b3d5-d7da-41c8-9855-88be912bb437"></a><a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>  </h2>
<p class="First">Sulfamethoxazole and trimethoprim-induced <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> may be an immune-mediated disorder. Severe cases of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> that are fatal or life threatening have been reported. <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> usually resolves within a week upon discontinuation of sulfamethoxazole and trimethoprim.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_79888e3c-3db9-4384-a454-c78036a254dd"></a><a name="section-6.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">Streptococcal Infections</span> and <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">Rheumatic Fever</span></h2>
<p class="First">The sulfonamides should not be used for the treatment of group A beta-hemolytic <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span>. In an established <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, they will not eradicate the streptococcus and, therefore, will not prevent sequelae such as <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_49adc947-12cf-4e2d-b2c1-2ba28b8b0d5d"></a><a name="section-6.4"></a><p></p>
<h2>
<span class="Italics">Clostridium Difficile </span>Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First"><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including sulfamethoxazole and trimethoprim, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.</p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bf1e6371-e89c-4faa-8077-f4d607860734"></a><a name="section-6.5"></a><p></p>
<h2>Sulfite Sensitivity</h2>
<p class="First">Sulfamethoxazole and trimethoprim injection contains sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> than in nonasthmatic people.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_62e71dbf-69df-4888-8b65-c04b50864c0c"></a><a name="section-6.6"></a><p></p>
<h2>Benzyl Alcohol</h2>
<p class="First">Contains benzyl alcohol. In newborn infants, benzyl alcohol has been associated with an increased incidence of neurological and other complications which are sometimes fatal.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0843c2a1-a8f2-40ce-88ee-2e37c3fd3130"></a><a name="section-6.7"></a><p></p>
<h2>Adjunctive Treatment With Leucovorin for <span class="Italics">Pneumocystis Jiroveci</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> </h2>
<p class="First">Treatment failure and excess mortality were observed when trimethoprim and sulfamethoxazole was used concomitantly with leucovorin for the treatment of HIV positive patients with <span class="Italics">Pneumocystis</span><span class="Italics">jiroveci </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> in a randomized placebo controlled trial.<span class="Sup">5</span> Coadministration of trimethoprim and sulfamethoxazole and leucovorin during treatment of <span class="Italics">Pneumocystis jiroveci</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> should be avoided. </p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_ef3d732a-29fb-4d89-aa3b-d8cdbe2e461c"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b0ede723-8f6b-4b31-b0fb-21dee6fdd26e"></a><a name="section-7.1"></a><p></p>
<h2>Development of Drug Resistant Bacteria</h2>
<p class="First">Prescribing sulfamethoxazole and trimethoprim injection in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b092341f-a70e-4853-87c9-013d49561892"></a><a name="section-7.2"></a><p></p>
<h2>General</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5c54bee0-5380-4995-8ae4-4ade97cb7498"></a><a name="section-7.2.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">Folate Deficiency</span></h3>
<p class="First">Sulfamethoxazole and trimethoprim injection should be given with caution to patients with impaired renal or hepatic function, to those with possible <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span> (e.g., the elderly, chronic alcoholics, patients receiving anticonvulsant therapy, patients with <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption syndrome</span>, and patients in <span class="product-label-link" type="condition" conceptid="4090739" conceptname="Nutritional disorder">malnutrition</span> states) and to those with severe allergies or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. </p>
<p>Hematological changes indicative of <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folic acid deficiency</span> may occur in elderly patients or in patients with preexisting <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folic acid deficiency</span> or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>. These effects are reversible by folinic acid therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a843373d-984a-4945-89b2-7d7190f65f50"></a><a name="section-7.2.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span></h3>
<p class="First">In glucose-6-phosphate dehydrogenase deficient individuals, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> may occur. This reaction is frequently dose-related (see <span class="Bold"><a href="#i4i_clinical_pharmacology_id_454f69d7-ec87-4198-9e11-2fdb093377f9">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#i4i_dosage_admin_id_f8e9e6f6-444e-4d17-b9e3-824ae240f57d">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f81628fd-e6a3-42a7-a91c-26ac5e613824"></a><a name="section-7.2.3"></a><p></p>
<h3>Infusion Reactions</h3>
<p class="First">Local irritation and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> due to extravascular infiltration of the infusion have been observed with sulfamethoxazole and trimethoprim. If these occur the infusion should be discontinued and restarted at another site.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d5db79e9-63bb-43b1-8182-ff149444884c"></a><a name="section-7.2.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h3>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in non-diabetic patients treated with sulfamethoxazole and trimethoprim are seen rarely, usually occurring after a few days of therapy. Patients with renal dysfunction, liver disease, <span class="product-label-link" type="condition" conceptid="4090739" conceptname="Nutritional disorder">malnutrition</span> or those receiving high doses of sulfamethoxazole and trimethoprim are particularly at risk.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_48e556d2-2811-422b-8735-4c63ce8c7eb1"></a><a name="section-7.2.5"></a><p></p>
<h3>Phenylalanine Metabolism</h3>
<p class="First">Trimethoprim has been noted to impair phenylalanine metabolism, but this is of no significance in phenylketonuric patients on appropriate dietary restriction.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_66698ed7-8f6d-4c0d-833f-48bc53afcd8e"></a><a name="section-7.2.6"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">Porphyria</span> and <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span></h3>
<p class="First">As with all drugs containing sulfonamides, caution is advisable in patients with <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span> or thyroid dysfunction.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d75576eb-1b5f-4d75-910f-bd9b6b912796"></a><a name="section-7.3"></a><p></p>
<h2>Use in the Treatment of <span class="Italics">Pneumocystis <span class="Italics">Jiroveci</span></span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> in Patients with <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">Acquired Immunodeficiency Syndrome</span> (AIDS)</h2>
<p class="First">AIDS patients may not tolerate or respond to sulfamethoxazole and trimethoprim in the same manner as non-AIDS patients. The incidence of side effects, particularly <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and elevated aminotransferase (transaminase) values, with sulfamethoxazole and trimethoprim therapy in AIDS patients who are being treated for <span class="Italics">Pneumocystis jiroveci </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> has been reported to be greatly increased compared with the incidence normally associated with the use of sulfamethoxazole and trimethoprim in non-AIDS patients. The incidence of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> appears to be increased in AIDS patients receiving sulfamethoxazole and trimethoprim. Adverse effects are generally less severe in patients receiving sulfamethoxazole and trimethoprim for prophylaxis. A history of mild intolerance to sulfamethoxazole and trimethoprim in AIDS patients does not appear to predict intolerance of subsequent secondary prophylaxis.<span class="Sup">6</span> However, if a patient develops <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any sign of adverse reaction, therapy with sulfamethoxazole and trimethoprim should be reevaluated (see<span class="Bold"><span class="Underline"><a href="#i4i_warnings_id_9db29e7b-aa2a-4396-9537-a48184e3f49a">WARNINGS</a></span></span>).</p>
<p>Coadministration of sulfamethoxazole and trimethoprim and leucovorin should be avoided with <span class="Italics">Pneumocystis jiroveci </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (see <span class="Bold"><a href="#i4i_warnings_id_9db29e7b-aa2a-4396-9537-a48184e3f49a">WARNINGS</a></span>).</p>
<p>High dosage of trimethoprim, as used in patients with <span class="Italics">Pneumocystis jiroveci</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, induces a progressive but reversible increase of serum potassium concentrations in a substantial number of patients. Even treatment with recommended doses may cause <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> when trimethoprim is administered to patients with underlying disorders of potassium metabolism, with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, or if drugs known to induce <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> are given concomitantly. Close monitoring of serum potassium is warranted in these patients.</p>
<p>During treatment, adequate fluid intake and urinary output should be ensured to prevent <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>. Patients who are â€œslow acetylatorsâ€? may be more prone to idiosyncratic reactions to sulfonamides.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_15cf38cd-5104-46b1-a1fd-03c26ae9bfe9"></a><a name="section-7.4"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be counseled that antibacterial drugs including sulfamethoxazole and trimethoprim injection should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. It does not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). </p>
<p>Patients should be instructed to maintain an adequate fluid intake in order to prevent <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span> and stone formation.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_6ff95f57-cfb3-474f-b772-1deecad31ee1"></a><a name="section-7.5"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Complete blood counts should be done frequently in patients receiving sulfamethoxazole and trimethoprim; if a significant reduction in the count of any formed blood element is noted, sulfamethoxazole and trimethoprim should be discontinued. Urinalyses with careful microscopic examination and renal function tests should be performed during therapy, particularly for those patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_id_066c9a05-a9dc-43e8-b1d1-b61f6a47d075"></a><a name="section-7.6"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> with <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> has been reported.</p>
<p>It has been reported that sulfamethoxazole and trimethoprim may prolong the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients who are receiving the anticoagulant warfarin. This interaction should be kept in mind when sulfamethoxazole and trimethoprim is given to patients already on anticoagulant therapy, and the coagulation time should be reassessed.</p>
<p>Sulfamethoxazole and trimethoprim may inhibit the hepatic metabolism of phenytoin. Sulfamethoxazole and trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 39% and decreased the phenytoin metabolic clearance rate by 27%. When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect. </p>
<p>Sulfonamides can also displace methotrexate from plasma protein binding sites and can compete with the renal transport of methotrexate, thus increasing free methotrexate concentrations.</p>
<p>There have been reports of marked but reversible <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> with coadministration of sulfamethoxazole and trimethoprim and cyclosporine in renal transplant recipients.</p>
<p>Increased digoxin blood levels can occur with concomitant sulfamethoxazole and trimethoprim therapy, especially in elderly patients. Serum digoxin levels should be monitored.</p>
<p>Increased sulfamethoxazole blood levels may occur in patients who are also receiving indomethacin. </p>
<p>Occasional reports suggest that patients receiving pyrimethamine as <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> prophylaxis in doses exceeding 25 mg weekly may develop <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span> if sulfamethoxazole and trimethoprim is prescribed.</p>
<p>The efficacy of tricyclic antidepressants can decrease when coadministered with sulfamethoxazole and trimethoprim.</p>
<p>Like other sulfonamide-containing drugs, sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics.</p>
<p>In the literature, a single case of toxic <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span> has been reported after concomitant intake of sulfamethoxazole and trimethoprim and amantadine.</p>
<p>In the literature, three cases of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> in elderly patients have been reported after concomitant intake of sulfamethoxazole and trimethoprim and an angiotensin converting enzyme inhibitor.<span class="Sup">7, 8</span></p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_923b8091-5e14-4c11-8874-064fd0923a44"></a><a name="section-7.7"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Sulfamethoxazole and trimethoprim, specifically the trimethoprim component, can interfere with a serum methotrexate assay as determined by the competitive binding protein technique (CBPA) when a bacterial dihydrofolate reductase is used as the binding protein. No interference occurs, however, if methotrexate is measured by a radioimmunoassay (RIA). </p>
<p>The presence of sulfamethoxazole and trimethoprim may also interfere with the JaffÃ© alkaline picrate reaction assay for creatinine, resulting in overestimations of about 10% in the range of normal values.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_a9147755-de6f-44cb-baff-8c9e8d9298e8"></a><a name="section-7.8"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0f20ca59-e95a-44a9-ace8-bcc2ea0544c4"></a><a name="section-7.8.1"></a><p></p>
<h3>Carcinogenesis</h3>
<p class="First">Long-term studies in animals to evaluate carcinogenic potential have not been conducted with sulfamethoxazole and trimethoprim.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_966364ad-5a81-48a7-aee8-394eec6e025a"></a><a name="section-7.8.2"></a><p></p>
<h3>Mutagenesis</h3>
<p class="First">Bacterial mutagenic studies have not been performed with sulfamethoxazole and trimethoprim in combination. Trimethoprim was demonstrated to be nonmutagenic in the Ames assay. No chromosomal damage was observed in human leukocytes cultured <span class="Italics">in vitro</span> with sulfamethoxazole and trimethoprim alone or in combination; the concentrations used exceeded blood levels of these compounds following therapy with sulfamethoxazole and trimethoprim. Observations of leukocytes obtained from patients treated with sulfamethoxazole and trimethoprim revealed no chromosomal abnormalities. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6fef15a8-0867-449a-a981-684efc56b593"></a><a name="section-7.8.3"></a><p></p>
<h3>Impairment of Fertility</h3>
<p class="First">No adverse effects on fertility or general reproductive performance were observed in rats given oral dosages as high as 350 mg/kg/day sulfamethoxazole plus 70 mg/kg/day trimethoprim.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_898aae9d-a5c5-43ca-8a59-825178a963c9"></a><a name="section-7.9"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_ec160bec-f993-40e7-b230-b643533d3321"></a><a name="section-7.9.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_pregnancy_C_id_d3943b9a-5ec1-4add-8c10-61b32cee31cf"></a><a name="section-7.9.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">In rats, oral doses of 533 mg/kg or 200 mg/kg produced teratologic effects manifested mainly as <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palates</span>.</p>
<p>The highest dose which did not cause <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palates</span> in rats was 512 mg/kg sulfamethoxazole or 192 mg/kg trimethoprim when administered separately. In two studies in rats, no teratology was observed when 512 mg/kg of sulfamethoxazole was used in combination with 128 mg/kg of trimethoprim. In one study, however, <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palates</span> were observed in one litter out of 9 when 355 mg/kg of sulfamethoxazole was used in combination with 88 mg/kg of trimethoprim.</p>
<p>In some rabbit studies, an overall increase in fetal loss (dead and resorbed and malformed conceptuses) was associated with doses of trimethoprim six times the human therapeutic dose. </p>
<p>While there are no large, well-controlled studies on the use of sulfamethoxazole and trimethoprim in pregnant women, Brumfitt and Pursell,<span class="Sup">9</span>Â  in a retrospective study, reported the outcome of 186 pregnancies during which the mother received either placebo or sulfamethoxazole and trimethoprim. The incidence of congenital abnormalities was 4.5% (3 of 66) in those who received placebo and 3.3% (4 of 120) in those receiving sulfamethoxazole and trimethoprim. There were no abnormalities in the 10 children whose mothers received the drug during the first trimester. In a separate survey, Brumfitt and Pursell also found no congenital abnormalities in 35 children whose mothers had received oral sulfamethoxazole and trimethoprim at the time of conception or shortly thereafter.</p>
<p>Because sulfamethoxazole and trimethoprim may interfere with folic acid metabolism, sulfamethoxazole and trimethoprim injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_ccdb1a0c-7721-450a-bc5b-92b6599e6cca"></a><a name="section-7.9.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First">See <span class="Bold"><span class="Underline"><a href="#i4i_contraindications_id_c4b1862b-37bf-46ac-872b-f06baa73f1c4">CONTRAINDICATIONS</a></span></span>section.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_29daaf40-878b-4680-8ada-9cfd11a2d5d6"></a><a name="section-7.10"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">See<span class="Bold"><span class="Underline"><a href="#i4i_contraindications_id_c4b1862b-37bf-46ac-872b-f06baa73f1c4">CONTRAINDICATIONS</a></span></span>section.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_fd9e9a15-f30d-4952-abc2-f2f8de2d0eb1"></a><a name="section-7.11"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Sulfamethoxazole and trimethoprim is contraindicated for infants younger than 2 months of age (seeÂ  <span class="Bold"><span class="Underline"><a href="#i4i_contraindications_id_c4b1862b-37bf-46ac-872b-f06baa73f1c4">CONTRAINDICATIONS</a></span></span> section).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_427ac219-296e-4935-80e7-8c4eae4fc81f"></a><a name="section-7.12"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of sulfamethoxazole and trimethoprim did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.</p>
<p>There may be an increased risk of severe adverse reactions in elderly patients, particularly when complicating conditions exist, e.g., impaired kidney and/or liver function, possible <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span>, or concomitant use of other drugs. Severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, generalized bone marrow suppression (see <span class="Bold"><span class="Underline"><a href="#i4i_warnings_id_9db29e7b-aa2a-4396-9537-a48184e3f49a">WARNINGS</a></span></span>and <span class="Bold"><span class="Underline"><a href="#i4i_adverse_effects_id_c7c517a1-1fea-49b4-b049-b7b0d2d15b73">ADVERSE REACTIONS</a></span><a href="#i4i_adverse_effects_id_c7c517a1-1fea-49b4-b049-b7b0d2d15b73"></a></span>sections), a specific decrease in platelets (with or without <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>), and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> are the most frequently reported severe adverse reactions in elderly patients. In those concurrently receiving certain diuretics, primarily thiazides, an increased incidence of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> with <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> has been reported. Increased digoxin blood levels can occur with concomitant sulfamethoxazole and trimethoprim therapy, especially in elderly patients. Serum digoxin levels should be monitored. Hematological changes indicative of <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folic acid deficiency</span> may occur in elderly patients. These effects are reversible by folinic acid therapy. Appropriate dosage adjustments should be made for patients with impaired kidney function and duration of use should be as short as possible to minimize risks of undesired reactions (see <span class="Bold"><span class="Underline"><a href="#i4i_dosage_admin_id_f8e9e6f6-444e-4d17-b9e3-824ae240f57d">DOSAGE AND ADMINISTRATION</a></span><a href="#i4i_dosage_admin_id_f8e9e6f6-444e-4d17-b9e3-824ae240f57d"></a></span>section). The trimethoprim component of sulfamethoxazole and trimethoprim may cause <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> when administered to patients with underlying disorders of potassium metabolism, with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> or when given concomitantly with drugs known to induce <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, such as angiotensin converting enzyme inhibitors. Close monitoring of serum potassium is warranted in these patients. Discontinuation of sulfamethoxazole and trimethoprim treatment is recommended to help lower potassium serum levels. </p>
<p>Pharmacokinetics parameters for sulfamethoxazole were similar for geriatric subjects and younger adult subjects. The mean maximum serum trimethoprim concentration was higher and mean renal clearance of trimethoprim was lower in geriatric subjects compared with younger subjects (see<span class="Bold"><a href="#i4i_clinical_pharmacology_id_454f69d7-ec87-4198-9e11-2fdb093377f9">CLINICAL PHARMACOLOGY</a>).</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_c7c517a1-1fea-49b4-b049-b7b0d2d15b73"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most common adverse effects are <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>) and <span class="product-label-link" type="condition" conceptid="4070025" conceptname="Cutaneous hypersensitivity">allergic skin reactions</span> (such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>). <span class="Bold">FATALITIES ASSOCIATED WITH THE ADMINISTRATION OF SULFONAMIDES, ALTHOUGH RARE, HAVE OCCURRED DUE TO SEVERE REACTIONS, INCLUDING <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">STEVENS-JOHNSON SYNDROME</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">TOXIC EPIDERMAL NECROLYSIS</span>, FULMINANT <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">HEPATIC NECROSIS</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">AGRANULOCYTOSIS</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">APLASTIC ANEMIA</span> AND OTHER <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">BLOOD DYSCRASIAS</span> (SEE <span class="Underline"><a href="#i4i_warnings_id_9db29e7b-aa2a-4396-9537-a48184e3f49a">WARNINGS</a></span> SECTION). </span>Local reaction, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and slight irritation on IV administration are infrequent. <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span> has rarely been observed.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0db6d5b9-edb9-430d-bca2-f6c0f17dbb2d"></a><a name="section-8.1"></a><p></p>
<h2>Hematologic</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span>, <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>, <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0cf9e30e-c053-4aa3-9ca1-e67722a08044"></a><a name="section-8.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, allergic <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, Henoch-Schoenlein <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>-like syndrome, generalized <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruptions</span>, conjunctival and scleral injection, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. In addition, <span class="product-label-link" type="condition" conceptid="320749" conceptname="Polyarteritis nodosa">periarteritis nodosa</span> and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> have been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c343c770-9a35-471d-857e-f3473eb5e78c"></a><a name="section-8.3"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> (including <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> and <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>), elevation of serum transaminase and bilirubin, <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous enterocolitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_430d6bb3-91b8-4cec-a4ae-79e4ded427cd"></a><a name="section-8.4"></a><p></p>
<h2>Genitourinary</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, BUN and serum creatinine elevation, toxic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span> with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, and <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2ac8c2be-9e7a-4a09-8dfb-ca83be3efd73"></a><a name="section-8.5"></a><p></p>
<h2>Metabolic and Nutritional</h2>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></span></p>
<p>See<span class="Bold"><a href="#i4i_precautions_id_ef3d732a-29fb-4d89-aa3b-d8cdbe2e461c">PRECAUTIONS</a>,</span><span class="Bold">Use in the Treatment of <span class="Italics">Pneumocystis </span></span><span class="Bold"><span class="Italics">Jiroveci </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> inÂ  Patients with <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">Acquired Immunodeficiency Syndrome</span> (AIDS).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_71a6ca20-ded0-4775-8dc6-a849177e92cf"></a><a name="section-8.6"></a><p></p>
<h2>Neurologic</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic meningitis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuritis</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e5865324-ffaf-4a7a-b40d-f6d405d13ef6"></a><a name="section-8.7"></a><p></p>
<h2>Psychiatric</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_470e6793-dc2f-4f00-81c1-b53f87d3333e"></a><a name="section-8.8"></a><p></p>
<h2>Endocrine</h2>
<p class="First">The sulfonamides bear certain chemical similarities to some goitrogens, diuretics (acetazolamide and the thiazides) and oral hypoglycemic agents. Cross-sensitivity may exist with these agents. <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">Diuresis</span> and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> have occurred rarely in patients receiving sulfonamides.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_27c6f188-f559-4cb7-a82b-3190b5012f07"></a><a name="section-8.9"></a><p></p>
<h2>Musculoskeletal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>. Isolated cases of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported with sulfamethoxazole and trimethoprim, mainly in AIDS patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bd596857-67ac-4f7c-bf45-a9b807693b0f"></a><a name="section-8.10"></a><p></p>
<h2>Respiratory</h2>
<p class="First">Pulmonary infiltrates.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2c7749ae-0441-4dff-8f9c-b5d63321f957"></a><a name="section-8.11"></a><p></p>
<h2>Miscellaneous</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_477635f1-0004-4503-8f75-19ab8bbf1b6a"></a><a name="section-8.12"></a><p></p>
<h2>Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of trimethoprim and sulfamethoxazole. Because these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure:</p>
<ul>
<li>Thrombotic <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenia purpura</span></li>
<li><span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">Idiopathic thrombocytopenic purpura</span></li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_8802e221-627b-418d-9858-20ce690369bf"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cb19e217-1531-46fc-b168-712ee5abc38c"></a><a name="section-9.1"></a><p></p>
<h2>Acute</h2>
<p class="First">Since there has been no extensive experience in humans with single doses of sulfamethoxazole and trimethoprim injection in excess of 25 mL (2000 mg sulfamethoxazole and 400 mg trimethoprim), the maximum tolerated dose in humans is unknown. Signs and symptoms of overdosage reported with sulfonamides include <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">colic</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> and <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span> may be noted. <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood dyscrasias</span> and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> are potential late manifestations of overdosage.</p>
<p>Signs of acute overdosage with trimethoprim include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>.</p>
<p>General principles of treatment include the administration of intravenous fluids if urine output is low and renal function is normal. Acidification of the urine will increase renal elimination of trimethoprim. The patient should be monitored with blood counts and appropriate blood chemistries, including electrolytes. If a significant <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasia</span> or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> occurs, specific therapy should be instituted for these complications. Peritoneal dialysis is not effective and hemodialysis is only moderately effective in eliminating trimethoprim and sulfamethoxazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4c17f979-396a-499a-a9e5-459828b88cca"></a><a name="section-9.2"></a><p></p>
<h2>Chronic</h2>
<p class="First">Use of sulfamethoxazole and trimethoprim injection at high doses and/or for extended periods of time may cause <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> manifested as <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and/or <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span>. If signs of <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> occur, the patient should be given leucovorin 5 to 15 mg daily until normal hematopoiesis is restored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1a84629a-0a69-4d32-93fd-7f2b3d5211e3"></a><a name="section-9.3"></a><p></p>
<h2>Animal Toxicity</h2>
<p class="First">The LD<span class="Sub">50</span> of sulfamethoxazole and trimethoprim injection in mice is 700 mg/kg or 7.3 mL/kg; in rats and rabbits the LD<span class="Sub">50</span> is &gt; 500 mg/kg or &gt; 5.2 mL/kg. The vehicle produced the same LD<span class="Sub">50</span> in each of these species as the active drug.</p>
<p>The signs and symptoms noted in mice, rats and rabbits with sulfamethoxazole and trimethoprim or its vehicle at the high IV doses used in acute toxicity studies included <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, decreased motor activity, loss of righting reflex, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, and/or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_f8e9e6f6-444e-4d17-b9e3-824ae240f57d"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">SULFAMETHOXAZOLE AND TRIMETHOPRIM INJECTION IS</span><span class="Bold">CONTRAINDICATED IN PEDIATRIC PATIENTS LESS THAN 2 MONTHS OF AGE.</span> CAUTIONâ€”SULFAMETHOXAZOLE AND TRIMETHOPRIM INJECTION MUST BE DILUTED IN 5% DEXTROSE IN WATER SOLUTION PRIOR TO ADMINISTRATION. DO NOT MIX SULFAMETHOXAZOLE AND TRIMETHOPRIM INJECTION WITH OTHER DRUGS OR SOLUTIONS. RAPID INFUSION OR BOLUS INJECTION MUST BE AVOIDED.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_479ab501-eca5-4367-a678-e7bf65a25108"></a><a name="section-10.1"></a><p></p>
<h2>Dosage</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8fc606e1-3451-4666-8d29-45884c3b8eac"></a><a name="section-10.1.1"></a><p></p>
<h3>Children and Adults </h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d3cc5f89-e00b-4038-a1bc-124d8b4deeb2"></a><a name="section-10.1.1.1"></a><p></p>
<h4>
<span class="Italics">Pneumocystis</span><span class="Italics"><span class="Underline">Jiroveci</span></span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></h4>
<p class="First">Total daily dose is 15 to 20 mg/kg (based on the trimethoprim component) given in 3 or 4 equally divided doses every 6 to 8 hours for up to 14 days. One investigator noted that a total daily dose of 10 to 15 mg/kg was sufficient in 10 adult patients with normal renal function.<span class="Sup">10</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_93e6e5b1-d7cb-460b-b2b4-b9093e3529c4"></a><a name="section-10.1.1.2"></a><p></p>
<h4>Severe <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> and Shigellosis</h4>
<p class="First">Total daily dose is 8 to 10 mg/kg (based on the trimethoprim component) given in 2 or 4 equally divided doses every 6, 8 or 12 hours for up to 14 days for severe <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> and 5 days for shigellosis. The maximum recommended daily dose is 60 mL per day.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4845799d-00e1-42e7-86c0-eb1a16198bd8"></a><a name="section-10.1.1.3"></a><p></p>
<h4>For Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h4>
<p class="First">When renal function is impaired, a reduced dosage should be employed using the following table:  </p>
<a name="id_c0169eda-59a2-40fd-bc97-82233178dfbf"></a><table border="single" width="349">
<col width="49.9%">
<col width="49.9%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold"><span class="Bold">Creatinine</span></span></p>
<span class="Bold">Clearance (mL/min)</span>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First"><span class="Bold">Recommended</span></p>
<span class="Bold">Dosage Regimen</span>
</td>
</tr>
<tr>
<td align="center" valign="top">Above 30</td>
<td align="center" valign="top">Usual standard regimen</td>
</tr>
<tr>
<td align="center" valign="top">15 to 30</td>
<td align="center" valign="top">1â?„2 the usual regimen</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="top">Below 15</td>
<td class="Botrule" align="center" valign="top">Use not recommended</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0901c2aa-9aa7-463b-952d-620365104b70"></a><a name="section-10.1.1.4"></a><p></p>
<h4>Method of Preparation</h4>
<p class="First">Sulfamethoxazole and trimethoprim injection must be diluted. EACH 5 ML SHOULD BE ADDED TO 125 ML OF 5% DEXTROSE IN WATER. After diluting with 5% dextrose in water the solution should not be refrigerated and should be used within 6 hours. If a dilution of 5 mL per 100 mL of 5% dextrose in water is desired, it should be used within 4 hours. If upon visual inspection there is cloudiness or evidence of crystallization after mixing, the solution should be discarded and a fresh solution prepared.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d49f5b19-c948-4434-830e-dbc16b3e178f"></a><a name="section-10.1.1.5"></a><p></p>
<h4>Multidose Vials</h4>
<p class="First">After initial entry into the vial, the remaining contents must be used within 48 hours.</p>
<p>The following infusion systems have been tested and found satisfactory: unit-dose glass containers; unit-dose polyvinyl chloride and polyolefin containers. No other systems have been tested and therefore no others can be recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_63ecce5f-e16e-4d0e-b001-c383511a7d5b"></a><a name="section-10.1.1.6"></a><p></p>
<h4>Dilution</h4>
<p class="First">EACH 5 ML OF SULFAMETHOXAZOLE AND TRIMETHOPRIM INJECTION SHOULD BE ADDED TO 125 ML OF 5% DEXTROSE IN WATER. </p>
<p><span class="Italics">Note: In those instances where fluid restriction is desirable,</span> each 5 mL may be added to 75 mL of 5% dextrose in water. Under these circumstances the solution should be mixed just prior to use and should be administered within 2 hours. If upon visual inspection there is cloudiness or evidence of crystallization after mixing, the solution should be discarded and a fresh solution prepared.</p>
<p>DO NOT MIX SULFAMETHOXAZOLE AND TRIMETHOPRIM INJECTION 5% DEXTROSE IN WATER WITH DRUGS OR SOLUTIONS IN THE SAME CONTAINER. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_57af9133-181d-4d50-9f0e-be76d469e8e0"></a><a name="section-10.2"></a><p></p>
<h2>Administration</h2>
<p class="First">The solution should be given by intravenous infusion over a period of 60 to 90 minutes. Rapid infusion or bolus injection must be avoided. Sulfamethoxazole and trimethoprim injection should not be given intramuscularly. </p>
<p><span class="Bold">Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit. </span></p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_b6b44d27-c669-4c11-a2b5-2e229e5cae36"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Sulfamethoxazole and Trimethoprim Injection USP, 80 mg and 16 mg are supplied as follows:</p>
<a name="id_f3abcf83-a51a-4715-9a28-10d4447b745c"></a><table border="none" width="400">
<col width="21.6%">
<col width="31.5%">
<col width="27.0%">
<col width="19.9%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top"><span class="Bold">NDC Numbers</span></td>
<td class="Toprule" align="left" valign="top"><span class="Bold">Sulfamethoxazole, USP</span></td>
<td class="Toprule" align="left" valign="top"><p class="First"><span class="Bold">Trimethoprim, USP</span></p></td>
<td align="left" valign="top"><span class="Bold">Size</span></td>
</tr>
<tr>
<td align="left" valign="top">0703<span class="Bold">-9503-</span>03</td>
<td align="left" valign="top">80 mg/mL</td>
<td align="left" valign="top">16 mg/mL</td>
<td align="left" rowspan="2" valign="top">
<p class="First">5 mL</p>
<p>Single</p>dose vial</td>
</tr>
<tr><td align="left" colspan="3" valign="top"></td></tr>
<tr>
<td align="left" valign="top">0703-<span class="Bold">9514-</span>03</td>
<td align="left" valign="top">80 mg/mL</td>
<td align="left" valign="top">16 mg/mL</td>
<td align="left" valign="top">
<p class="First">10 mL</p>
<p>Multiple</p>dose vial</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">0703-<span class="Bold">9526-</span>01</td>
<td align="left" valign="top">80 mg/mL</td>
<td align="left" valign="top">16 mg/mL</td>
<td align="left" valign="top">
<p class="First">30 mL</p>
<p>Multiple</p>dose vial</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
</tbody>
</table>
<p>Â 5 mL single dose amber vials packaged 10 per carton.</p>
<p>10 mL multiple dose amber vials packaged 10 per carton.</p>
<p>30 mL multiple dose amber vials packaged individually. </p>
<p>Store at 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled Room Temperature].</p>
<p><span class="Bold">DO NOT REFRIGERATE.</span></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_7c4ef61c-c522-49db-bfb2-85b5f8d9b18d"></a><a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>Grose WE, Bodey GP, Loo TL. Clinical Pharmacology of Intravenously Administered Trimethoprim-Sulfamethoxazole. <span class="Italics">Antimicrob Agents Chemother</span>. Mar 1979;15:447-451. </li>
<li>Siber GR, Gorham C, Durbin W, Lesko L, Levin MJ. Pharmacology of Intravenous Trimethoprim-Sulfamethoxazole in Children and Adults. <span class="Italics">Current Chemotherapy and Infectious Diseases</span>, American Society for Microbiology, Washington, D.C., 1980, Vol. 1, pp. 691-692. </li>
<li>Rudoy RC, Nelson JD, Haltalin KC. <span class="Italics">Antimicrobial Agents Chemother</span>. May 1974;5:439â€“443.</li>
<li>National Committee for Clinical Laboratory Standards. <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically</span>; Approved Standard â€“ Fourth Edition. NCCLS Document M7â€“A4, Vol.17, No. 2, NCCLS, Wayne, PA, January, 1997.</li>
<li>Safrin S, Lee BL, Sande MA. Adjunctive folinic acid with trimethoprim-sulfamethoxazole for <span class="Italics">Pneumocystis carinii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> in AIDS patients is associated with an increased risk of therapeutic failure and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="Italics">J Infect Dis</span>. 1994 Oct;170(4):912-7. </li>
<li>Hardy DW, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of <span class="Italics">Pneumocystis carinii</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> in patients with the <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immunodeficiency syndrome</span>. <span class="Italics">N Engl J Med</span>. 1992; 327: 1842â€“1848.</li>
<li>Marinella Mark A. 1999. Trimethoprim-induced <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>: An analysis of reported cases. <span class="Italics">Gerontol</span>. 45:209â€“212.</li>
<li>Margassery, S. and B. Bastani. 2002. Life threatening <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> and <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> secondary to trimethoprim-sulfamethoxazole treatment. <span class="Italics">J. Nephrol</span>. 14:410â€“414.</li>
<li>Brumfitt W, Pursell R. Trimethoprim/Sulfamethoxazole in the Treatment of <span class="product-label-link" type="condition" conceptid="4265485" conceptname="Bacteriuria">Bacteriuria</span> in Women. <span class="Italics">J Infect Dis</span>. Nov 1973;128 (Suppl):S657-S663. </li>
<li>Winston DJ, Lau WK, Gale RP, Young LS. Trimethoprim- Sulfamethoxazole for the Treatment of <span class="Italics">Pneumocystis carinii</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>. <span class="Italics">Ann Intern Med</span>. June 1980;92:762-769.</li>
</ol>
<p class="First">Manufactured In Israel By:<br>Teva Pharmaceutical Ind. Ltd.<br>Kfar Saba, 44102, Israel<br></p>
<p><br>Manufactured For:<br>Teva Pharmaceuticals USA<br>Sellersville, PA 18960</p>
<p>Rev. I 4/2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_5868013e-0618-4aa0-b43c-a210ac40d8fa"></a><a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL, Part 1 of 2</h1>
<div class="Figure"><img alt=" Sulfamethoxazole and Trimethoprim Injection, USP 5 mL Single Dose Vial, 10 Vial Carton, Part 1 of 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b89b5502-ce87-45a6-a43c-9891da3cfca4&amp;name=d39fe231-d9a6-4396-86ff-5ff23ee40e81-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_b892d504-4223-4c92-adbe-6ee348181d98"></a><a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL, Part 2 of 2</h1>
<div class="Figure"><img alt=" Sulfamethoxazole and Trimethoprim Injection, USP 5 mL Single Dose Vial, 10 Vial Carton, Part 2 of 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b89b5502-ce87-45a6-a43c-9891da3cfca4&amp;name=d39fe231-d9a6-4396-86ff-5ff23ee40e81-04.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aeb93852-e1cc-4d40-a6da-03761e5f6e1c"></a><a name="section-14.1"></a><p></p>
<h2>Sulfamethoxazole and Trimethoprim Injection, USP 5 mL Single Dose Vial, 10 Vial Carton Text</h2>
<p class="First"><span class="Bold">NDC 0703-9503-03                                                      Rx only </span></p>
<p><span class="Bold">Sulfamethoxazole and Trimethoprim<br>Injection USP </span></p>
<p><span class="Bold">Sulfamethoxazole                           400 mg/5 mL (80 mg/mL) <br>Trimethoprim                                   80 mg/5 mL (16 mg/mL) </span></p>
<p>For IV Infusion Only <br>5 mL Single Dose Vial<br><span class="Bold">10 Vials<br></span><span class="Bold">Must be diluted with 5% dextrose injection prior to administration.</span></p>
<p><span class="Bold">TEVA</span></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_cc3cefad-18e1-4f1e-9469-eb8e11922e35"></a><a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL, Part 1 of 2</h1>
<div class="Figure"><img alt=" Sulfamethoxazole and Trimethoprim Injection, USP 10 mL Multiple Dose Vial, 10 Vial Carton, Part 1 of 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b89b5502-ce87-45a6-a43c-9891da3cfca4&amp;name=d39fe231-d9a6-4396-86ff-5ff23ee40e81-05.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_a0297d14-7932-4b05-8082-ccc12f4eb244"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL, Part 2 of 2</h1>
<div class="Figure"><img alt=" Sulfamethoxazole and Trimethoprim Injection, USP 10 mL Multiple Dose Vial, 10 Vial Carton, Part 2 of 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b89b5502-ce87-45a6-a43c-9891da3cfca4&amp;name=d39fe231-d9a6-4396-86ff-5ff23ee40e81-06.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2a19c780-4ec0-45de-a602-c344e444cd7a"></a><a name="section-16.1"></a><p></p>
<h2>Sulfamethoxazole and Trimethoprim Injection, USP 10 mL Multiple Dose Vial, 10 Vial Carton Text</h2>
<p class="First"><span class="Bold">NDC 0703-9514-03                                                      Rx only </span></p>
<p><span class="Bold">Sulfamethoxazole and Trimethoprim<br>Injection USP </span></p>
<p><span class="Bold">Sulfamethoxazole                         800 mg/10 mL (80 mg/mL) <br>Trimethoprim                               160 mg/10 mL (16 mg/mL) </span></p>
<p>For IV Infusion Only <br>10 mL Multiple Dose Vial<br><span class="Bold">10 Vials<br></span><span class="Bold">Must be diluted with 5% dextrose injection prior to administration.</span></p>
<p><span class="Bold">TEVA </span></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_ad69324b-7b99-4ae9-8d2d-436d3ff0c624"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt=" Sulfamethoxazole and Trimethoprim Injection, USP 30 mL Multiple Dose Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b89b5502-ce87-45a6-a43c-9891da3cfca4&amp;name=d39fe231-d9a6-4396-86ff-5ff23ee40e81-07.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_59c571dd-3d05-4cd6-a6d7-50aea2e7b978"></a><a name="section-17.1"></a><p></p>
<h2>Sulfamethoxazole and Trimethoprim Injection, USP 30 mL Multiple Dose Vial Carton Text</h2>
<p class="First"><span class="Bold">NDC 0703-9526-01                                    Rx only </span></p>
<p><span class="Bold">Sulfamethoxazole<br>and Trimethoprim<br>Injection USP </span></p>
<p><span class="Bold">Sulfamethoxazole                         2400 mg/30 mL<br>                                                             (80 mg/mL) <br>Trimethoprim                                 480 mg/30 mL<br>                                                             (16 mg/mL) </span></p>
<p>For IV Infusion Only </p>
<p>30 mL Multiple Dose Vial</p>
<p><span class="Bold">Must be diluted with 5% dextrose<br>injection prior to administration.</span></p>
<p><span class="Bold">TEVA </span></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SULFAMETHOXAZOLE AND TRIMETHOPRIMÂ 		
					</strong><br><span class="contentTableReg">sulfamethoxazole and trimethoprim injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0703-9503</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SULFAMETHOXAZOLE</strong> (SULFAMETHOXAZOLE) </td>
<td class="formItem">SULFAMETHOXAZOLE</td>
<td class="formItem">80Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>TRIMETHOPRIM</strong> (TRIMETHOPRIM) </td>
<td class="formItem">TRIMETHOPRIM</td>
<td class="formItem">16Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem">10Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>DIETHANOLAMINE</strong></td>
<td class="formItem">3Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem">100Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">400Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM METABISULFITE</strong></td>
<td class="formItem">1Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0703-9503-03</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0703-9503-01</td>
<td class="formItem">5 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA073303</td>
<td class="formItem">11/01/1991</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SULFAMETHOXAZOLE AND TRIMETHOPRIMÂ 		
					</strong><br><span class="contentTableReg">sulfamethoxazole and trimethoprim injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0703-9514</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SULFAMETHOXAZOLE</strong> (SULFAMETHOXAZOLE) </td>
<td class="formItem">SULFAMETHOXAZOLE</td>
<td class="formItem">80Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>TRIMETHOPRIM</strong> (TRIMETHOPRIM) </td>
<td class="formItem">TRIMETHOPRIM</td>
<td class="formItem">16Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem">10Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>DIETHANOLAMINE</strong></td>
<td class="formItem">3Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem">100Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">400Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM METABISULFITE</strong></td>
<td class="formItem">1Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0703-9514-03</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0703-9514-01</td>
<td class="formItem">10 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA073303</td>
<td class="formItem">11/01/1991</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SULFAMETHOXAZOLE AND TRIMETHOPRIMÂ 		
					</strong><br><span class="contentTableReg">sulfamethoxazole and trimethoprim injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0703-9526</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SULFAMETHOXAZOLE</strong> (SULFAMETHOXAZOLE) </td>
<td class="formItem">SULFAMETHOXAZOLE</td>
<td class="formItem">80Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>TRIMETHOPRIM</strong> (TRIMETHOPRIM) </td>
<td class="formItem">TRIMETHOPRIM</td>
<td class="formItem">16Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem">10Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>DIETHANOLAMINE</strong></td>
<td class="formItem">3Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem">100Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">400Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM METABISULFITE</strong></td>
<td class="formItem">1Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0703-9526-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA073303</td>
<td class="formItem">11/01/1991</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Teva Parenteral Medicines, Inc.
							(794362533)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d39fe231-d9a6-4396-86ff-5ff23ee40e81</div>
<div>Set id: b89b5502-ce87-45a6-a43c-9891da3cfca4</div>
<div>Version: 8</div>
<div>Effective Time: 20130820</div>
</div>
</div>Â <div class="DistributorName">Teva Parenteral Medicines, Inc.</div></p>
</body></html>
